TransCode Therapeutics, Inc.
RNAZ
$0.38
-$0.02-5.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.78% | -43.29% | -31.70% | -29.81% | -14.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.35% | -29.55% | -12.95% | -11.10% | 4.21% |
| Operating Income | 19.35% | 29.55% | 12.95% | 11.10% | -4.21% |
| Income Before Tax | 9.66% | 23.82% | 3.64% | 9.81% | -5.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.66% | 23.82% | 3.64% | 9.81% | -5.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.66% | 23.82% | 3.64% | 9.81% | -5.59% |
| EBIT | 19.35% | 29.55% | 12.95% | 11.10% | -4.21% |
| EBITDA | 19.31% | 29.68% | 13.08% | 11.25% | -4.10% |
| EPS Basic | 74.97% | -- | -- | -- | -- |
| Normalized Basic EPS | 74.97% | -- | -- | -- | -- |
| EPS Diluted | 74.97% | -- | -- | -- | -- |
| Normalized Diluted EPS | 74.97% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 8,328.99% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 8,328.99% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |